Biocon Ltd, a prominent biotechnology company engaged in manufacturing biotechnology products and research services, reported extraordinary financial results for Q2FY26. Financial Highlights:
Biocon Ltd
-(BIOCON)
XNSE:BIOCON, XBOM:BIOCON
Biocon Q1 FY26 Earnings Results
Biocon Limited, engaged in the manufacture of biotechnology products and research services, reported its Q1 FY26 Earnings results. Q1 FY26 Earnings Results
Biocon Ltd Q4FY25; 106% rise in Profits
Biocon is engaged in the business of manufacture of biotechnology products and research services.(Source : 202003-01 Annual Report Page No:195) Financial Results:
Biocon Ltd Q3FY25; 89% fall in Profits
Biocon is engaged in the business of manufacture of biotechnology products and research services.(Source : 202003-01 Annual Report Page No:195) Financial Results:
Biocon Ltd Q2FY25; 84% fall in Profits
Biocon is engaged in the business of manufacture of biotechnology products and research services.(Source : 202003-01 Annual Report Page No:195) Financial Results:
Biocon Ltd Q1FY25; 479% rise in Profits
Biocon is engaged in the business of manufacture of biotechnology products and research services. Financial Results: Biocon Ltd reported Revenues for Q1FY25
Biocon Ltd Q4FY24; 46% fall in Profits
Biocon is engaged in the business of manufacture of biotechnology products and research services.(Source : 202003-01 Annual Report Page No:195) Financial Results:
Biocon Ltd Q3FY24; 34% rise in Revenue
Biocon is engaged in the business of manufacture of biotechnology products and research services. Financial Results: Biocon Ltd reported Revenues for Q3FY24
Biocon Ltd Q2FY24; 111% rise in Profits
Biocon is engaged in the business of manufacture of biotechnology products and research services. Financial Results: Biocon Ltd reported Revenues for Q2FY24
Biocon Ltd Q1FY24; 11% fall in Profits
Biocon is engaged in the business of manufacture of biotechnology products and research services.(Source : 202003-01 Annual Report Page No:195) Financial Results:
Biocon Ltd.: Driving Growth in Pharmaceutical Industry.
Stock Data: TickerNSE: BIOCONExchangeNSEIndustryPHARMACEUTICALS Price Performance: Last 5 Days+1.43%YTD-7.18%Last 12 Months-22.16%As on 16-06-2023 Company Description: Biocon is India's premier biotechnology company. It
Alphagraph | Biocon Limited (NSE: BIOCON): Q4FY23 Results Out; Total Income rises 58% YoY.
Biocon is a prominent player in the biotechnology industry, specializing in the manufacturing of biotechnology products and offering research services. With a
Biocon Limited (BIOCON) Q3 FY23 Earnings Concall Transcript
Biocon Limited (NSE:BIOCON) Q3 FY23 Earnings Concall dated Feb. 15, 2023. Corporate Participants: Saurabh Paliwal -- Head - Investor Relations Kiran Mazumdar Shaw -- Biocon Ltd.
Biocon ltd.(NSE: BIOCON) Ltd. : Q3 FY23 Results Out; Total Income rise 35% YoY
Biocon Limited (NSE:BIOCON) is an Indian multinational biopharmaceutical company based in Bangalore, India. The company was founded in 1978 by Kiran Mazumdar-Shaw
Biocon Limited Q2 FY23 Earnings Conference Call Insights
Key highlights from Biocon Limited (BIOCON) Q2 FY23 Earnings Concall Q&A Highlights: [00:23:49] Prakash Agarwal of Axis Capital asked about the mezzanine
Biocon Q2FY23 results out: Revenue up by 26%
Biocon Ltd reported a 49 percent slump in consolidated net profit at INR 82 crore for the quarter ended September 30, 2022.
Biocon Limited (BIOCON) Q2 FY23 Earnings Concall Transcript
Biocon Limited (NSE: BIOCON) Q2 FY23 Earnings Concall dated Nov. 14, 2022 Corporate Participants: Saurabh Paliwal -- Head, Investor Relations Kiran Mazumdar
Biocon Limited (BIOCON) Q1 FY23 Earnings Concall Transcript
Biocon Limited (NSE:BIOCON) Q1 FY23 Earnings Concall dated Jul. 27, 2022. Corporate Participants: Kiran Mazumdar Shaw -- Executive Chairperson Biocon Limited and Biocon Biologics
Infographic: Biocon opens this year with a stellar performance reporting 71% growth in profits
Biocon on Wednesday reported 71% year-on-year (YoY) jump in net profit to Rs 144 crore during Q1FY23, driven by sales of biosimilar
Biocon Limited (BIOCON) Q1 FY23 Earnings Concall Transcript
Biocon Limited (NSE : BIOCON) Q1 FY23 Earnings Concall dated July. 27, 2022 Corporate Participants: Kiran Mazumdar Shaw -- Executive Chairperson Biocon Limited and
Biocon Limited (BIOCON) Q4 2022 Earnings Concall Transcript
Biocon Limited (NSE: BIOCON) Q4 2022 earnings concall dated Apr. 29, 2022 Corporate Participants: Aishwarya Seetharam -- Head, Investor Relations Kiran Mazumdar Shaw -- Executive Chairperson